Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Too slow recruitment and no staff availability
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Maastricht University | OTHER |
Not provided
Not provided
Not provided
Not provided
This study evaluates the use of exhaled air analysis as tool to monitor the disease activity in Crohn's Disease (CD). This study is a validation of the previous findings. In this study the participant will be asked to donate exhaled air, blood samples and fecal samples. The breath samples will be used to measure various volatile metabolites in breath. The breath air will be next used to validate the previous findings. The blood samples will be used to define the origin of volatile metabolites in breath. Finally, the potential of exhaled breath analysis as non-invasive marker of diseases activity will be compared to established fecal calprotectin.
In the recent study(doi: 10.1097/Mib.0000000000000436) it was shown the potential of analysis of exhaled air to differentiate active and inactive state of Crohn's Disease (CD). Although, the molecules found in this cohort have shown potential to differentiate between CD patients in remission or with active disease, the validation of the outcomes has to be performed in new population. One crucial pathophysiologic factor in CD is excessive lipid peroxidation during oxidative stress, i.e. during overproduction of oxidants compared to the protective antioxidants. Oxidative stress is a potential aetiological factor and/or a triggering factor in CD. Many volatile compounds including hydrocarbons and aldehydes are produced during oxidative stress and they can be non-invasively measured in exhaled air 5, 6. However, exhaled breath contains volatile metabolites originating from previous or current uptake of environmental contaminants, and more interestingly from metabolism of foreign organisms (bacteria, viruses, fungi or yeasts). Therefore, it is important to study not only exhaled air but also blood in which blood borne volatile molecules can be measured. Since the current study also aims for validating the use of volatile molecules in exhaled air as non-invasive markers for disease activity in CD patients, the investigators will compare the outcome of exhaled air analysis with currently established non-invasive measure of disease activity, i.e. fecal calprotectin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Entire Cohort | This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Specimen sampling | Other | exhaled air samples blood samples fecal samples |
|
| Measure | Description | Time Frame |
|---|---|---|
| Volatile organic compounds profile: volatile compound concentrations in breath | The exhaled air samples will be used to first validate the volatile compounds for disease activity in Crohn's Disease. | The samples will be collected within no more than one week before scheduled colonoscopy. |
| Metabolic profile: metabolite concentrations in blood | Blood samples will be used to better understand the origin of the volatile compounds in breath. | The samples will be collected within no more than one week before scheduled colonoscopy. |
| Fecal calprotectin (µg/g) in fecal samples | Fecal calprotectin will be measured as indicator of the migration of neutrophils to the intestinal mucosa. | The samples will be collected within no more than one week before scheduled colonoscopy. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Our target population will consist of individuals with established diagnosis of Crohn's Disease (CD). The target population will include male and female between the ages of 18 and 65 years and standard BMI (between 19 and 30). Potential study participants will be excluded if having any disease compromising immune system (such as HIV positive status or patients after organ transplantations), diagnosis of any liver disease, active and untreated tuberculosis and chemotherapy agents. All potential participants must have scheduled appointment for colonoscopy.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Agnieszka Smolinska, PhD | Dartmouth/Maastricht University | Principal Investigator |
| Corey A Siegel, PhD,MD | Dartmouth-Hitchcock Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03766 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24713999 | Background | Smolinska A, Hauschild AC, Fijten RR, Dallinga JW, Baumbach J, van Schooten FJ. Current breathomics--a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J Breath Res. 2014 Jun;8(2):027105. doi: 10.1088/1752-7155/8/2/027105. Epub 2014 Apr 8. | |
| 26199990 | Result | Bodelier AG, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, van den Heuvel T, Masclee AA, Jonkers D, Pierik MJ, van Schooten FJ. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach. Inflamm Bowel Dis. 2015 Aug;21(8):1776-85. doi: 10.1097/MIB.0000000000000436. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
exhaled air samples blood samples fecal samples
| D007410 | Intestinal Diseases |